Eli Lilly Marks 150 Years of Innovation

Why this is here: Eli Lilly’s global research and development investment reached $10.9 billion in 2024, representing over 24% of the company’s total revenue.

Eli Lilly and Company celebrates 150 years of bringing innovative therapies to global markets. The pharmaceutical company focuses on conditions like diabetes, obesity, Alzheimer’s disease, and cancer.

In 2024, Eli Lilly invested $10.9 billion in research and development—over 24% of its revenue. Roughly 58 million patients worldwide, including over 100,000 in Romania, benefited from Lilly’s therapies last year.

A team of 47,000 specialists supports this work globally. In Romania, Lilly has operated for 32 years, employing 100 professionals and providing over 30 innovative medicines to doctors and patients. The company also participates in local health policy improvements and clinical trials.

Lilly continues research into complex conditions, but challenges remain in expanding access to these treatments and fully understanding long-term effects. The company plans to strengthen partnerships and continue supporting scientific progress.